Ogeda is a clinical-stage drug discovery company that invents and develops small molecule drugs targeting G-Protein Coupled Receptors. Ogeda leads the development of NK3 antagonists for the treatment of hormone-dependent pathologies in Women's Health. Its lead product, fezolinetant has shown positive results in a Phase IIa proof-of-concept clinical study in Menopausal Hot Flashes, and studies in PolyCystic Ovary Syndrome and Uterine Fibroids are in progress. Ogeda's portfolio further includes several pre-clinical drug discovery programs in endocrine, CNS and/or inflammatory disorders.
Ogeda was acquired by Astellas Pharma on April 2, 2017
When was Ogeda founded?
Ogeda was founded in 1994.
Who are Ogeda key executives?
Ogeda's key executives are Rui Patrao, Graeme Fraser and Hamid Hoveyda.
How many employees does Ogeda have?
Ogeda has 17 employees.
Who are Ogeda competitors?
Competitors of Ogeda include Organoid Therapeutics, Vitabiotics and Asarina Pharma.
Where is Ogeda headquarters?
Ogeda headquarters is located at Marie Curiesquare 50/building 5, Anderlecht.
Where are Ogeda offices?
Ogeda has an office in Anderlecht.
How many offices does Ogeda have?
Ogeda has 1 office.
Receive alerts for 300+ data fields across thousands of companies